SAN DIEGO, CA, Dec. 4 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) announced today that Margot Northey, Ph.D., is leaving the Board of
Directors effective as of today to pursue other interests.
Jay M. Short, Ph.D., Chairman of Nventa's Board of Directors, commented
on the Board change: "As the former Dean of the School of Business at Queen's
University, Margot's knowledge, combined with her experience from other Board
positions, was a tremendous asset to the Nventa Board. We will miss her and
wish her continued success in all of her future endeavors."
"We are very appreciative of Margot's contribution to the Board," said
Gregory M. McKee, Nventa's President and Chief Executive Officer. "With the
Board's support, we have advanced the development of HspE7, our
investigational therapeutic vaccine for human papillomavirus (HPV)-related
diseases, into a Phase 1 clinical trial in women with cervical dysplasia."
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa
Biopharmaceuticals Corporation, please visit the Company's website located at
For further information:
For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Direct: (858) 202-4945,